(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Chinook Therapeutics (KDNY) said Tuesday that dosing has been initiated in a phase 1 clinical trial evaluating CHK-336 in adult healthy volunteers. ...
Chinook Therapeutics (KDNY) has an average rating of buy and price targets ranging from $25 to $40, according to analysts polled by Capital IQ. (MT...
Chinook Therapeutics (KDNY) reported Q4 earnings Thursday of $0.14 per diluted share, compared with a loss of $1.24 per share a year earlier. Two analysts...
| Address | 400 Fairview Avenue North Seattle, Washington 98109 |
| Phone | +1.206.485.7241 |
| Number of Employees | 152 |
| Recent SEC Filing | 05/12/2022 10-Q |
| Chairman, President & Chief Executive Officer | Eric L. Dobmeier |
| Chief Operating Officer | Tom Frohlich |
| Chief Financial Officer | Eric Hands Claude Bjerkholt |
| Chief Scientific Officer | Andrew King |
| Price Open | $13.39 |
| Previous Close | $12.59 |
| 52 Week Range | $10.48 - 19.85 |
| Market Capitalization | $694.7 M |
| Shares Outstanding | 55.2 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 08/11/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$2.10 |
| Beta vs. S&P 500 | N/A |
| Revenue | $15.1 M |
| Net Profit Margin | -199.39% |
| Return on Equity | -31.18% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
